|
1
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: the impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chan JM, Jou RM and Carroll PR: The
relative impact and future burden of prostate cancer in the United
States. J Urol. 172:S13–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huncharek M, Haddock KS, Reid R and
Kupelnick B: Smoking as a risk factor for prostate cancer: a
meta-analysis of 24 prospective cohort studies. Am J Public Health.
100:693–701. 2010. View Article : Google Scholar
|
|
4
|
Stewart SL, Cardinez CJ, Richardson LC, et
al: Surveillance for cancers associated with tobacco use - United
States, 1999–2004. MMWR Surveill Summ. 57:1–33. 2008.PubMed/NCBI
|
|
5
|
Colditz G: Consensus conference: smoking
and prostate cancer. Cancer Causes Control. 7:560–562. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hickey K, Do KA and Green A: Smoking and
prostate cancer. Epidemiol Rev. 23:115–125. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rohrmann S, Linseisen J, Allen N, et al:
Smoking and the risk of prostate cancer in the European Prospective
Investigation into Cancer and Nutrition. Br J Cancer. 108:708–714.
2013. View Article : Google Scholar :
|
|
8
|
Zu K and Giovannucci E: Smoking and
aggressive prostate cancer: a review of the epidemiologic evidence.
Cancer Causes Control. 20:1799–1810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Roomi MW, Kalinovsky T, Rath M, et al:
Down-regulation of urokinase plasminogen activator and matrix
metalloproteinases and up-regulation of their inhibitors by a novel
nutrient mixture in human prostate cancer cell lines PC-3 and
DU-145. Oncol Rep. 26:1407–1413. 2011.PubMed/NCBI
|
|
10
|
Yurchenco PD and Schittny JC: Molecular
architecture of basement membranes. FASEB J. 4:1577–1590.
1990.PubMed/NCBI
|
|
11
|
Barsky SH, Siegal GP, Jannotta F, et al:
Loss of basement membrane components by invasive tumors but not by
their benign counterparts. Lab Invest. 49:140–147. 1983.PubMed/NCBI
|
|
12
|
Liotta LA, Tryggvason K, Garbisa S, et al:
Metastatic potential correlates with enzymatic degradation of
basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liotta LA, Rao CN and Barsky SH: Tumor
invasion and the extracellular matrix. Lab Invest. 49:636–649.
1983.PubMed/NCBI
|
|
14
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Folkman J: Role of angiogenesis in tumor
growth and metastasis. Semin Oncol. 29:15–18. 2002. View Article : Google Scholar
|
|
16
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nelson AR, Fingleton B, Rothenberg ML, et
al: Matrix metalloproteinases: biologic activity and clinical
implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
18
|
Bérubé M, Deschambeault A, Boucher M, et
al: MMP-2 expression in uveal melanoma: differential activation
status dictated by the cellular environment. Mol Vis. 11:1101–1111.
2005.PubMed/NCBI
|
|
19
|
Garzetti G, Ciavattini A, Lucarini G, et
al: Tissue and serum metalloproteinase (MMP-2) expression in
advanced ovarian serous cystoadenocarcinomas: clinical and
prognostic implications. Anticancer Res. 15:2799–2804.
1995.PubMed/NCBI
|
|
20
|
Gohji K, Fujimoto N, Hara I, Fujii A,
Gotoh A, et al: Serum matrix metalloproteinase-2 and its density in
men with prostate cancer as a new predictor of disease extension.
Int J Cancer. 79:96–101. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lokeshwar BL: MMP inhibition in prostate
cancer. Ann NY Acad Sci. 878:271–289. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shariat SF, Karam JA and Roehrborn CG:
Blood biomarkers for prostate cancer detection and prognosis.
Future Oncol. 3:449–461. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Achbarou A, Kaiser S, Tremblay G, et al:
Urokinase overproduction results in increased skeletal metastasis
by prostate cancer cells in vivo. Cancer Res. 54:2372–2377.
1994.PubMed/NCBI
|
|
24
|
Pryor WA and Stone K: Oxidants in
cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and
peroxynitrite. Ann NY Acad Sci. 686:12–27. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hecht SS: Tobacco smoke carcinogens and
lung cancer. J Natl Cancer Inst. 91:1194–1210. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Birrane G, Li H, Yang S, et al: Cigarette
smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in
prostate cancer cells: nuclear HO-1 promotes vascular endothelial
growth factor secretion. Int J Oncol. 42:1919–1928. 2013.PubMed/NCBI
|
|
27
|
Aragon-Ching JB: Active surveillance for
prostate cancer: has the time finally come? J Clin Oncol.
28:e265–e266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dilly AK, Ekambaram P, Guo Y, et al:
Platelet-type 12-lipoxygenase induces MMP9 expression and cellular
invasion via activation of PI3K/Akt/NF-κB. Int J Cancer.
133:1784–1791. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tian TV, Tomavo N, Huot L, et al:
Identification of novel TMPRSS2:ERG mechanisms in prostate cancer
metastasis: involvement of MMP9 and PLXNA2. Oncogene. 24:2204–2214.
2014. View Article : Google Scholar
|
|
30
|
Delassus GS, Cho H, Hoang S and Eliceiri
GL: Many new down- and up-regulatory signaling pathways, from known
cancer progression suppressors to matrix metalloproteinases, differ
widely in cells of various cancers. J Cell Physiol. 224:549–558.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Verslegers M, Lemmens K, Van Hove I and
Moons L: Matrix metalloproteinase-2 and -9 as promising benefactors
in development, plasticity and repair of the nervous system. Prog
Neurobiol. 105:60–78. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jinka R, Kapoor R, Sistla PG, Raj TA and
Pande G: Alterations in cell-extracellular matrix interactions
during progression of cancers. Int J Cell Biol. 2012:2191962012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoo SY and Kwon SM: Angiogenesis and its
therapeutic opportunities. Mediators Inflamm. 2013:1271702013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grässel S and Bauer RJ: Collagen XVI in
health and disease. Matrix Biol. 32:64–73. 2013. View Article : Google Scholar
|
|
35
|
Goel HL, Li J, Kogan S and Languino LR:
Integrins in prostate cancer progression. Endocr Relat Cancer.
15:657–664. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vandewalle C, Van Roy F and Berx G: The
role of the ZEB family of transcription factors in development and
disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar
|
|
37
|
Xiao LJ, Lin P, Lin F, et al: ADAM17
targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to
promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724.
2012.
|
|
38
|
Ashida S, Nakagawa H, Katagiri T, et al:
Molecular features of the transition from prostatic intraepithelial
neoplasia (PIN) to prostate cancer: genome-wide gene-expression
profiles of prostate cancers and PINs. Cancer Res. 64:5963–5972.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sathyanarayana UG, Padar A, Suzuki M, et
al: Aberrant promoter methylation of laminin-5-encoding genes in
prostate cancers and its relationship to clinicopathological
features. Clin Cancer Res. 9:6395–6400. 2003.PubMed/NCBI
|
|
40
|
Rodriguez LG, Wu X and Guan JL:
Wound-healing assay. Methods Mol Biol. 294:23–29. 2005.
|
|
41
|
Gumbiner BM: Cell adhesion: the molecular
basis of tissue architecture and morphogenesis. Cell. 84:345–357.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sheetz MP, Felsenfeld DP and Galbraith CG:
Cell migration: regulation of force on
extracellular-matrix-integrin complexes. Trends Cell Biol. 8:51–54.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhen Y, Ye Y, Yu X, et al: Reduced CTGF
expression promotes cell growth, migration, and invasion in
nasopharyngeal carcinoma. PLoS One. 8:e649762013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jinka R, Kapoor R, Sistla PG, Raj TA and
Pande G: Alterations in cell-extracellular matrix interactions
during progression of cancers. Int J Cell Biol. 2012:2191962012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Okegawa T, Pong RC, Li Y and Hsieh JT: The
role of cell adhesion molecule in cancer progression and its
application in cancer therapy. Acta Biochim Pol. 51:445–457.
2004.PubMed/NCBI
|
|
46
|
Zhao Y, Zhou T, Li A, et al: A potential
role of collagens expression in distinguishing between premalignant
and malignant lesions in stomach. Anat Rec (Hoboken). 292:692–700.
2009. View Article : Google Scholar
|
|
47
|
Fischer H, Salahshor S, Stenling R, et al:
COL11A1 in FAP polyps and in sporadic colorectal tumors. BMC
Cancer. 1:172001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu YH, Chang TH, Huang YF, et al: COL11A1
promotes tumor progression and predicts poor clinical outcome in
ovarian cancer. Oncogene. 33:3432–3440. 2014. View Article : Google Scholar
|
|
49
|
Nabha SM, dos Santos EB, Yamamoto HA, et
al: Bone marrow stromal cells enhance prostate cancer cell invasion
through type I collagen in an MMP-12 dependent manner. Int J
Cancer. 122:2482–2490. 2008. View Article : Google Scholar : PubMed/NCBI
|
